Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270918 · ClinicalTrials.gov registry record · Phase 1
Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
A Phase 1 study of Thrombosis, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02270918 is a Phase 1 study of Thrombosis that has completed, run by Thomas Jefferson University. The registered enrollment target is 12 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02270918, a Phase 1 study of Thrombosis, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA approved drug derived from blood that is used as an antidote to treat people with bleeding associated with taking the well-known anticoagulant warfarin. This is a Phase I, placebo-controlled, single site, open-label, crossover trial to evaluate the reversibility apixaban anticoagulation with Kcentra.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
- DRUG Kcentra
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hosptial - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-11 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02270918
The ClinicalTrials.gov registry entry for NCT02270918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (97% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02270918 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02270918 about?
NCT02270918 is a clinical study titled "Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra". Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA approved drug derived from b...
What is the current status of trial NCT02270918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-11. Estimated completion is 2014-12.
What conditions does trial NCT02270918 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT02270918?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), Kcentra (DRUG).
Who is sponsoring clinical trial NCT02270918?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02270918 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers
COMPLETED · Phase 1
-
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment
COMPLETED · Phase 1
-
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
COMPLETED · Phase 1
-
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.